|
Name |
Cholan-16-one, 23-methyl-, (5alpha,20xi)-
|
Molecular Formula | C25H42O | |
IUPAC Name* |
(5R,8R,9S,10S,13S,14S,17R)-10,13-dimethyl-17-[(2R)-4-methylpentan-2-yl]-1,2,3,4,5,6,7,8,9,11,12,14,15,17-tetradecahydrocyclopenta[a]phenanthren-16-one
|
|
SMILES |
C[C@H](CC(C)C)[C@H]1C(=O)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCCC4)C)C
|
|
InChI |
InChI=1S/C25H42O/c1-16(2)14-17(3)23-22(26)15-21-19-10-9-18-8-6-7-12-24(18,4)20(19)11-13-25(21,23)5/h16-21,23H,6-15H2,1-5H3/t17-,18-,19-,20+,21+,23+,24+,25+/m1/s1
|
|
InChIKey |
RVDADQFBPPLLTP-IQGOHZNHSA-N
|
|
Synonyms |
Cholan-16-one, 23-methyl-, (5.alpha.,20.xi.)-
|
|
CAS | NA | |
PubChem CID | 91743343 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 358.6 | ALogp: | 8.4 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 17.1 | Aromatic Rings: | 4 |
Heavy Atoms: | 26 | QED Weighted: | 0.54 |
Caco-2 Permeability: | -4.733 | MDCK Permeability: | 0.00001050 |
Pgp-inhibitor: | 0.982 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.996 |
30% Bioavailability (F30%): | 0.992 |
Blood-Brain-Barrier Penetration (BBB): | 0.501 | Plasma Protein Binding (PPB): | 96.67% |
Volume Distribution (VD): | 1.396 | Fu: | 1.65% |
CYP1A2-inhibitor: | 0.149 | CYP1A2-substrate: | 0.318 |
CYP2C19-inhibitor: | 0.253 | CYP2C19-substrate: | 0.908 |
CYP2C9-inhibitor: | 0.352 | CYP2C9-substrate: | 0.128 |
CYP2D6-inhibitor: | 0.042 | CYP2D6-substrate: | 0.099 |
CYP3A4-inhibitor: | 0.629 | CYP3A4-substrate: | 0.386 |
Clearance (CL): | 19.366 | Half-life (T1/2): | 0.072 |
hERG Blockers: | 0.762 | Human Hepatotoxicity (H-HT): | 0.229 |
Drug-inuced Liver Injury (DILI): | 0.866 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.585 | Maximum Recommended Daily Dose: | 0.045 |
Skin Sensitization: | 0.94 | Carcinogencity: | 0.13 |
Eye Corrosion: | 0.954 | Eye Irritation: | 0.675 |
Respiratory Toxicity: | 0.971 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002305 | 0.432 | D04DJN | 0.489 | ||||
ENC000125 | 0.429 | D09NNA | 0.440 | ||||
ENC003337 | 0.427 | D00VZZ | 0.432 | ||||
ENC001475 | 0.411 | D0U3GL | 0.415 | ||||
ENC001764 | 0.409 | D0Y7LD | 0.396 | ||||
ENC002882 | 0.409 | D0Q6NZ | 0.394 | ||||
ENC005239 | 0.409 | D06XMU | 0.365 | ||||
ENC000961 | 0.407 | D07BSQ | 0.360 | ||||
ENC003458 | 0.396 | D0B4RU | 0.360 | ||||
ENC001008 | 0.396 | D08QKJ | 0.359 |